Clinical Trials Logo

Stage IV NSCLC clinical trials

View clinical trials related to Stage IV NSCLC.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03812549 Completed - Stage IV NSCLC Clinical Trials

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Start date: January 18, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation therapy (SBRT) and low dose radiotherapy (LDRT) in treating patients with stage IV non-small cell lung cancer (NSCLC). At least 29 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.

NCT ID: NCT01864681 Completed - Advanced Cancer Clinical Trials

Combination of Metformin With Gefitinib to Treat NSCLC

CGMT
Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor (EGFR) mutations

NCT ID: NCT01438307 Completed - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains limited at < 12 months median overall survival. New approaches are needed for second line chemotherapy treatment. Cabazitaxel-XRP6258 has shown increased overall survival in metastatic prostate cancer and it is hopeful it can do the same in advanced NSCLC.